Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer.

Cell Death Discov · 2025 · PMC11772833 · PMID 39870629

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Clinical applications and future goals Based on the aforementioned, there is an increasing trend in gemcitabine sensitivity associated with p53 gene mutation.

also in 63,971 other papers

did not reach statistical significanceno p-value reported

However, these differences did not reach statistical significance due to the limited samples (PFS: 23.2 ± 8.1 months, 10.5 ± 3.1 months, 5.1 ± 1.4 months).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.